No Data
No Data
The Hong Kong stock market is restructuring the value of pharmaceuticals! Hengrui Medicine has received a premium binding from AstraZeneca, and the stock price once rose over 20%.
① Does the offshore strategy mean that "technology platform premium + international certification" is replacing the traditional PE valuation method as the core logic for valuing Innovative Drugs companies? ② With JACOBIO-B narrowing its annual loss by 56.6% through its core product Galidesivir, can it be inferred that China’s Innovative Drugs companies have broken through the industry curse of "burning money on R&D - ongoing losses"?
Express News | China Medical System (00867) Released Its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to ReShape Growth Momentum
How strong are the Hong Kong pharmaceutical stocks right now? The Innovative Drugs Index has risen over 30% this year, reaching a near 16-month high.
① The Innovative Drugs Index in the Hong Kong stock market has increased by over 30% this year; why can it compete with Technology stocks? ② There has been a "small peak" in the commercialization of individual stocks; how do Institutions perceive the future market direction?
China Medical System Holdings Insider Ups Holding During Year
Is the CRO Concept "Return of the King"? WuXi AppTec aggressively attacks, leading stocks celebrate after performance!
Release the signal?!
Hong Kong Stock Announcement Goldmine | CHINA TOWER's profit attributable to Shareholders for the fiscal year 2024 is 10.729 billion yuan, a year-on-year increase of 10%, with profitability continuously strengthening.
WUXI APPTEC (02359) released its annual results, with a profit attributable to the parent company of 9.353 billion yuan. The Operation continued to add around 1,000 new customers throughout the year; HAITIAN INT'L (01882) announced its annual performance, with a profit attributable to Shareholders of 3.08 billion yuan, an increase of 23.6% year-on-year.